LCN2 and neoplasm: These data indicate strong evidence that besides the NF-kB pathway, the JNK signaling axis is responsible for the TNF-α-mediated LCN2 induction and is a potential therapeutic target for PCa patients, considering that LCN2 has been recognized as a tumor-promoting component in the disease.